Immune Profile of Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM) Treated with Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) + Daratumumab (DARA) in the Second Line Immediately after Lenalidomide (LEN)

Xiaozhong Qian; Kathryn Newhall; Mark Tometsko; Chad Bjorklund; Jianglin Ma; Nizar J. Bahlis; David Siegel; Gary J. Schiller; Christy Samaras; Michael Sebag; Jesus G. Berdeja; Siddhartha Ganguly; Jeffrey V. Matous; Kevin W Song; Christopher S. Seet; Giampaolo Talamo; Shanthi Srinivas; Mirelis Acosta-Rivera; Michael Bar; Donald Quick; Bertrand Anz; Gustavo Fonseca; Donna Reece; Jorge Mouro; Amit Agarwal; Faiza Zafar; Anjan Thakurta

doi:10.1182/BLOOD.V130.SUPPL_1.1888.1888

Immune Profile of Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM) Treated with Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) + Daratumumab (DARA) in the Second Line Immediately after Lenalidomide (LEN)

Xiaozhong Qian
, Kathryn Newhall
, Mark Tometsko
, Chad Bjorklund
, Jianglin Ma
, Nizar J. Bahlis
, David Siegel
, Gary J. Schiller
, Christy Samaras
, Michael Sebag
, Jesus G. Berdeja
, Siddhartha Ganguly
, Jeffrey V. Matous
, Kevin W Song
, Christopher S. Seet
, Giampaolo Talamo
, Shanthi Srinivas
, Mirelis Acosta-Rivera
, Michael Bar
, Donald Quick

Bertrand Anz, Gustavo Fonseca, Donna Reece, Jorge Mouro, Amit Agarwal, Faiza Zafar, Anjan Thakurta

Celgene
University of Calgary
Hackensack University Medical Center
University of California, Los Angeles
Cleveland Clinic
Royal Victoria Hospital, Montreal, Canada
Tennessee Oncology, PLLC, Nashville, TN
University of Kansas
Colorado Blood Cancer Institute, Denver, CO
Vancouver General Hospital
UCLA Medical Center
Pennsylvania State University
United States Department of Veterans Affairs
Fundacion de Investigacion,, San Juan,, Puerto Rico
Stamford Hospital
Joe Arrington Caner Research Treatment Center, Lubbock, TX
17Tennessee Oncology, Chattanooga, TN
Florida Cancer Specialists, St Petersburg, FL
Princess Margaret Cancer Centre

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Blood
Volume	130
DOIs	https://doi.org/10.1182/BLOOD.V130.SUPPL_1.1888.1888
State	Published - Dec 7 2017
Externally published	Yes

Disciplines

Medicine and Health Sciences
Oncology
Internal Medicine

Access to Document

10.1182/BLOOD.V130.SUPPL_1.1888.1888License: Unspecified

Cite this

Qian, X., Newhall, K., Tometsko, M., Bjorklund, C., Ma, J., Bahlis, N. J., Siegel, D., Schiller, G. J., Samaras, C., Sebag, M., Berdeja, J. G., Ganguly, S., Matous, J. V., Song, K. W., Seet, C. S., Talamo, G., Srinivas, S., Acosta-Rivera, M., Bar, M., ... Thakurta, A. (2017). Immune Profile of Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM) Treated with Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) + Daratumumab (DARA) in the Second Line Immediately after Lenalidomide (LEN). Blood, 130. https://doi.org/10.1182/BLOOD.V130.SUPPL_1.1888.1888

Immune Profile of Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM) Treated with Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) + Daratumumab (DARA) in the Second Line Immediately after Lenalidomide (LEN). / Qian, Xiaozhong; Newhall, Kathryn; Tometsko, Mark et al.
In: Blood, Vol. 130, 07.12.2017.

Research output: Contribution to journal › Article › peer-review

Qian, X, Newhall, K, Tometsko, M, Bjorklund, C, Ma, J, Bahlis, NJ, Siegel, D, Schiller, GJ, Samaras, C, Sebag, M, Berdeja, JG, Ganguly, S, Matous, JV, Song, KW, Seet, CS, Talamo, G, Srinivas, S, Acosta-Rivera, M, Bar, M, Quick, D, Anz, B, Fonseca, G, Reece, D, Mouro, J, Agarwal, A, Zafar, F & Thakurta, A 2017, 'Immune Profile of Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM) Treated with Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) + Daratumumab (DARA) in the Second Line Immediately after Lenalidomide (LEN)', Blood, vol. 130. https://doi.org/10.1182/BLOOD.V130.SUPPL_1.1888.1888

@article{c27d81b5ff824c5998a8d7986b3685ba,

title = "Immune Profile of Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM) Treated with Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) + Daratumumab (DARA) in the Second Line Immediately after Lenalidomide (LEN)",

author = "Xiaozhong Qian and Kathryn Newhall and Mark Tometsko and Chad Bjorklund and Jianglin Ma and Bahlis, \{Nizar J.\} and David Siegel and Schiller, \{Gary J.\} and Christy Samaras and Michael Sebag and Berdeja, \{Jesus G.\} and Siddhartha Ganguly and Matous, \{Jeffrey V.\} and Song, \{Kevin W\} and Seet, \{Christopher S.\} and Giampaolo Talamo and Shanthi Srinivas and Mirelis Acosta-Rivera and Michael Bar and Donald Quick and Bertrand Anz and Gustavo Fonseca and Donna Reece and Jorge Mouro and Amit Agarwal and Faiza Zafar and Anjan Thakurta",

note = "Xiaozhong Qian, Kathryn Newhall, Mark Tometsko, Chad Bjorklund, Jianglin Ma, Nizar J. Bahlis, David Siegel, Gary J. Schiller, Christy Samaras, Michael Sebag, Jesus G. Berdeja, Siddhartha Ganguly, Jeffrey V. Matous, Kevin W Song, Christopher S.",

year = "2017",

month = dec,

day = "7",

doi = "10.1182/BLOOD.V130.SUPPL\_1.1888.1888",

language = "American English",

volume = "130",

journal = "Blood",

publisher = "American Society of Hematology",

}

TY - JOUR

T1 - Immune Profile of Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM) Treated with Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) + Daratumumab (DARA) in the Second Line Immediately after Lenalidomide (LEN)

AU - Qian, Xiaozhong

AU - Newhall, Kathryn

AU - Tometsko, Mark

AU - Bjorklund, Chad

AU - Ma, Jianglin

AU - Bahlis, Nizar J.

AU - Siegel, David

AU - Schiller, Gary J.

AU - Samaras, Christy

AU - Sebag, Michael

AU - Berdeja, Jesus G.

AU - Ganguly, Siddhartha

AU - Matous, Jeffrey V.

AU - Song, Kevin W

AU - Seet, Christopher S.

AU - Talamo, Giampaolo

AU - Srinivas, Shanthi

AU - Acosta-Rivera, Mirelis

AU - Bar, Michael

AU - Quick, Donald

AU - Anz, Bertrand

AU - Fonseca, Gustavo

AU - Reece, Donna

AU - Mouro, Jorge

AU - Agarwal, Amit

AU - Zafar, Faiza

AU - Thakurta, Anjan

N1 - Xiaozhong Qian, Kathryn Newhall, Mark Tometsko, Chad Bjorklund, Jianglin Ma, Nizar J. Bahlis, David Siegel, Gary J. Schiller, Christy Samaras, Michael Sebag, Jesus G. Berdeja, Siddhartha Ganguly, Jeffrey V. Matous, Kevin W Song, Christopher S.

PY - 2017/12/7

Y1 - 2017/12/7

UR - https://ashpublications.org/blood/article/130/Supplement%201/1888/71451/Immune-Profile-of-Patients-pts-with-Relapsed-and

U2 - 10.1182/BLOOD.V130.SUPPL_1.1888.1888

DO - 10.1182/BLOOD.V130.SUPPL_1.1888.1888

M3 - Article

VL - 130

JO - Blood

JF - Blood

ER -

Immune Profile of Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM) Treated with Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) + Daratumumab (DARA) in the Second Line Immediately after Lenalidomide (LEN)

Disciplines

Access to Document

Other files and links

Cite this